Stargardt disease, also known as Stargardt macular degeneration, is a genetic eye disorder that primarily affects the macula, the central part of the retina responsible for sharp, detailed vision. It is the most common form of inherited juvenile macular degeneration, typically presenting in childhood or adolescence, though some individuals may not experience symptoms until adulthood.
The condition is characterized by the progressive loss of central vision, making tasks such as reading, recognizing faces, and driving increasingly difficult. However, peripheral (side) vision is usually preserved. A hallmark sign of Stargardt disease is the accumulation of lipofuscin, a yellowish fatty byproduct of normal cell activity, in the retinal pigment epithelium (RPE). Over time, this buildup damages the light-sensitive photoreceptor cells in the macula, leading to vision loss.
Symptoms often begin with a slow, painless decrease in central vision. Patients may also experience sensitivity to bright lights (photophobia), delayed dark adaptation (difficulty adjusting from bright to dim light), and color vision abnormalities. The rate of progression varies widely among individuals, even within the same family.
Diagnosis typically involves a comprehensive eye examination, including visual acuity tests, visual field testing, and specialized imaging such as optical coherence tomography (OCT) and fundus autofluorescence (FAF). These imaging techniques help ophthalmologists visualize the characteristic lipofuscin deposits and assess the extent of macular damage. Genetic testing is also crucial to confirm the diagnosis and identify the specific gene mutations involved.
While a diagnosis of Stargardt disease can be challenging, understanding the condition is the first step in managing it effectively. Patients are encouraged to work closely with their eye care specialists to monitor their vision and explore available resources. Please consult your healthcare provider for personalized medical advice and management strategies.